Ownership Summary
A total of 5 institutions have reported a stake in Addex Therapeutics Ltd. (NASDAQ:ADXN) as of December 2025, according to recent 13F filings with the SEC.
- Institutional ownership in Addex Therapeutics edged up to 0.0% in December 2025, compared to 0.0% in September 2025.
- On a quarter-over-quarter basis, institutional holdings shifted by 206.53%, with a year-over-year a decrease of 16.67% in the count of filers.
- Of these 5 institutional investors, 2 increased their holdings in Addex Therapeutics, while 2 of them reduced positions, and 1 investors maintained their exposure.
- This class of investors increased its holdings in Addex Therapeutics to 610 shares for the 13F-cycle ending December 2025, up by 411 shares quarter on quarter, and down 14.49K shares year over year.
- As of December 31, 2025, MORGAN STANLEY held Addex Therapeutics's largest shareholding position with over 300 shares, representing 0.00% of total outstanding shares.
- Among the most significant buyers of Addex Therapeutics during December 2025 were MORGAN STANLEY (300), UBS Group AG (155).
- Leading sellers of Addex Therapeutics stock in December 2025 included GAMMA Investing LLC (40), SBI Securities Co., Ltd. (4).
- The top 5 institutional holders of Addex Therapeutics for the quarter ending December 2025 included MORGAN STANLEY (300), UBS Group AG (156), GAMMA Investing LLC (81), RHUMBLINE ADVISERS (72), SBI Securities Co., Ltd. (1).